Related Experiment Video
Updated: Aug 21, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary
Jeffry Florian1, Qin Sun2, Sarah J Schrieber3
1Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Pharmacodynamic (PD) biomarkers can streamline biosimilar development and approval, aligning with FDA guidance. A workshop convened experts to discuss leveraging PD biomarkers for more efficient biosimilar pathways.
Area of Science:
- Biopharmaceutical development
- Regulatory science
- Biomarker research
Background:
- US Food and Drug Administration (FDA) guidance allows biosimilar approval using pharmacokinetic and pharmacodynamic (PD) biomarker data.
- The application of this guidance for biosimilar approval has been limited in the past decade.
- There is a need to encourage broader use of PD biomarkers in biosimilar development.
Purpose of the Study:
- To encourage the use of PD biomarkers in biosimilar development and approval.
- To discuss the current and future role of PD biomarkers in improving biosimilar development efficiency.
- To summarize FDA initiatives and stakeholder experiences with PD biomarkers.
Main Methods:
- A two-day virtual public workshop was held on September 20-21, 2021.
- The workshop convened global regulators, biopharmaceutical developers, and academic researchers.
- The event focused on discussions and presentations regarding PD biomarkers for biosimilar development.
Main Results:
- The workshop served as a forum to discuss the current and potential future state of leveraging PD biomarkers.
- Initiatives by the FDA to advance biosimilar development were summarized.
- Stakeholder experiences and research efforts promoting broader PD biomarker application were described.
Conclusions:
- The workshop highlighted the importance of PD biomarkers in enhancing biosimilar development efficiency.
- Broader application of PD biomarkers could streamline the approval process for biosimilar products.
- Continued collaboration between regulators, industry, and academia is crucial for advancing biosimilar development.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Bioequivalence: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...